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Abstract
Adverse drug reactions (ADRs) are a major cause of hospital admissions, but recent data on the incidence and clinical
characteristics of ADRs which occur following hospital admission, are lacking. Patients admitted to twelve wards over a six-
month period in 2005 were assessed for ADRs throughout their admission. Suspected ADRs were recorded and analysed for
causality, severity and avoidability and whether they increased the length of stay. Multivariable analysis was undertaken to
identify the risk factors for ADRs. The 5% significance level was used when assessing factors for inclusion in multivariable
models. Out of the 3695 patient episodes assessed for ADRs, 545 (14.7%, 95% CI 13.6–15.9%) experienced one or more
ADRs. Half of ADRs were definitely or possibly avoidable. The patients experiencing ADRs were more likely to be older,
female, taking a larger number of medicines, and had a longer length of stay than those without ADRs. However, the only
significant predictor of ADRs, from the multivariable analysis of a representative sample of patients, was the number of
medicines taken by the patient with each additional medication multiplying the hazard of an ADR episode by 1.14 (95% CI
1.09, 1.20). ADRs directly increased length of stay in 147 (26.8%) patients. The drugs most frequently associated with ADRs
were diuretics, opioid analgesics, and anticoagulants. In conclusion, approximately one in seven hospital in-patients
experience an ADR, which is a significant cause of morbidity, increasing the length of stay of patients by an average of
0.25 days/patient admission episode. The overall burden of ADRs on hospitals is high, and effective intervention strategies
are urgently needed to reduce this burden.
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Introduction
Adverse drug reactions (ADRs) in hospitalised patients can be
divided into two broad categories: those that cause admission to
hospital, and those that occur in in-patients after hospital
admission. In a meta-analysis, using a random-effects model to
reduce heterogeneity, Lazarou et al [1] showed that the total
incidence of both categories of serious ADRs was 6.7%, of which
4.7% were responsible for admission and 2.1% occurred after
admission, with an overall fatality rate of 0.32%. A recent
Swedish study has also implicated ADRs as 7
th most common
cause of death [2]. In a study of almost 19000 admissions, we
were able to show that 6.5% of patient admissions to two
National Health Service (NHS) hospitals in the UK were related
to an ADR [3]. This incidence figure is broadly compatible with
pooled data from older studies [1,4], and with more recent studies
[5,6].
By contrast, data on ADRs occurring after hospital admissions
are poor. Older studies have suggested that between 10–20% of
patients suffer ADRs in hospital [7–10], while Lazarou et al
suggested that 10.9% of patients suffer ADRs of all severities as in-
patients [1]. A systematic review by Wiffen et al estimated that in
the NHS in England, 1.6 million bed days, equivalent to 13.6 (400-
bed) hospital equivalents annually are due to in-patient ADRs [4].
It is important to note that most of these data relate to studies that
are decades old. With the changing demographics, the well-known
predisposition of the elderly to ADRs, and the changes in medical
practice that have occurred over the last few decades, there is a
need for more data on the ADR burden in hospital in-patients.
As part of our overall strategy to determine the burden of ADRs
in hospitals, after the completion of our ADR hospital admission
study [3], we undertook a pilot study to establish the methodology
for determining the burden of ADRs in in-patients. This pilot
study of 125 in-patients showed that 19% of patients suffered
ADRs, with patients experiencing an ADR spending 6.5 days
longer in hospital than those without ADRs [11]. In this paper, we
report the results of our large-scale prospective study which further
explores the impact of ADRs on NHS hospital in-patients in terms
of incidence, length of stay, costs involved, and factors that
predispose patients to ADRs.
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4439Methods
Patients and settings
The study was conducted on 12 wards (9 medical and 3 surgical)
at the Royal Liverpool University Hospital (RLUH) over a six-
month period between June and December 2005. The RLUH is a
teaching hospital which serves a population of about 0.5 million
with a total annual activity of 90,000 admissions. The study
protocol was assessed and approved by the Liverpool Local
Research Ethics Committee and the audit department at the
RLUH, and the Research Ethics Committee at Liverpool John
Moores University.
Methods
For the purposes of this study, an ADR was defined according
to the definition of Edwards and Aronson [12]. ADRs were
identified on the basis that they were well recognised as evidenced
by their inclusion in either the Summary of Product Character-
istics [13] and/or the British National Formulary [14]. Only
ADRs that occurred during admission as a result of drugs initiated
or continued in hospital were included, while community acquired
longstanding ADRs that were treated during the hospital stay were
excluded (n=17, 2.3% of all ADRs detected). ADRs that
manifested no clinical signs, for example, suspected drug-induced
abnormalities in blood test results were differentiated from those
which caused clinical symptoms.
The study wards were a sample representative of the medical to
surgical ward ratio in the hospital. Intensive care units and more
specialist units such as the renal dialysis unit were excluded as our
focus was on ADRs occurring in wards that are found in most UK
general hospitals. The RLUH does not have psychiatric, paediatric
or obstetrics and gynaecology wards, and thus our estimate of the
incidence of ADRs excludes such patient groups. Patients admitted
to the study wards during the data collection period were identified
daily (Monday to Friday) by the research pharmacist using the
hospital Patient Administration System (PAS). Patients whose
admission did not include a weekday were therefore excluded, as
were patients recorded on the PAS system following the daily check
of ward lists, and discharged within one day prior to the next
morning.Studywardswerevisited daily bytheresearch pharmacist,
and patients’ drug charts, medical and nursing notes were reviewed
for evidence of an ADR. Objective markers of ADRs, e.g.
laboratory results, were identifiable from the patient notes and the
hospital computer system, while subjective markers of ADRs, for
example headache, nausea and rash were identified through patient
notes, discussion with the ward team and, where appropriate,
discussion with the affected patient.Clinicalstaffwereinformed that
the study was taking place and could also refer directly either in
person or through notification cards that were made available on
the wards. The clinical ward pharmacists were consulted regularly
regarding the possibility of ADRs on their designated wards.
Following completion of the ward based data-collection period,
retrospective case note analysis was performed to assess patient
outcomes and to ensure that all available details regarding the ADR
had been collected.
Suspected ADRs were classified in terms of causality [15] and
avoidability [16] according to validated algorithms and assessed
for suitability for Yellow Card Reporting to the Commission on
Human Medicines and to the Medicines and Healthcare products
Regulatory Agency (CHM/MHRA) [17]. ADRs were also
classified as either type A (dose-dependent and predictable from
the known pharmacology) or type B (idiosyncratic, no clear dose
response relationship, and not predictable from the known
pharmacology) according to the system introduced by Rawlins
and Thompson in 1977 [18]. We chose this classification instead of
the more recent DoTS classification [19] so that our data could be
compared with previous studies. We also recorded severity of the
ADRs according to the Hartwig severity scale [20], which was
adapted from our pilot study [11], and subsequently modified to
include two level 7 ADRs in order to differentiate between ADRs
which directly, and those which indirectly, cause death.
Analysis for causality, avoidability, severity and suitability for
yellow card reporting was done independently by investigators ED
and CG. Overall there was approximately 60% agreement in the
causality and avoidability assessments. Any discrepancies in
scoring were then discussed before consensus was achieved
between two investigators (ED and CG) in conjunction with the
chief investigator (MP). Nine (1.2%) suspected ADRs were
subsequently excluded by the investigating team, on the basis that
an ADR was unlikely to be drug related according to the Naranjo
algorithm [15]. The overall incidence of in-patient ADRs was
defined as the total number of in-patient episodes which resulted in
ADRs in relation to the total number of in-patient episodes in the
study wards during the study period.
The length of stay for each patient was recorded using PAS
data, enabling comparisons between patients with and without
ADRs. Analysis of whether the ADR directly increased the length
of stay, and the duration of this increase, was made following an
assessment of the clinical features of the underlying disease and
ADR, and after discussion with the ward team including the ward
pharmacist and medical staff, and assessment of relevant case-
notes. Clinical judgment was used to assess the additional length of
stay attributable to the ADR. Thus, for example, if a patient had
an ADR whilst waiting for nursing home placement, e.g.
antibiotic-related C. difficile diarrhoea and the wait for placement
independently exceeded the duration of the ADR, no additional
length of stay was attributed to the reaction. Conversely, if a
patient was ready for discharge, but an ADR occurred which
required the patient to stay in hospital, the additional length of stay
until recovery from the ADR was attributed to the reaction. All
drugs including the causative drug(s) were recorded for all patients
with ADRs. Given that there is no electronic system to capture
information on medicines prescribed within our hospital, with the
resources available, capturing information from all the patients
would have led to incomplete and inaccurate information. We
therefore decided to capture high quality data from a random
sample of 1 in 10 in-patients on the same study wards.
ADRs which occurred despite specific prophylaxis against the
ADR were recorded while the potential effect of polypharmacy on
ADRs was measured by comparing the number of regular
medicines taken by ADR patients on the first day of ADR with
the number of regular medicines taken for the control sample (1 in
10 patients), assessed on the day of the in-patient stay where the
patient received the maximum number of medicines. The most
frequent ADRs relative to usage were calculated by using data of
all drugs administered to one tenth of patients admitted. The
frequency of the drug group causing a suspected ADR was divided
by the number of times a drug in that class was administered in the
control sample of patients (if$1). The resulting ratio allowed drug
groups to be further ranked by frequency of ADRs relative to drug
use. The costs to the NHS were estimated using number of bed-
days for additional length of stay based on the standard daily costs
of NHS hospital episodes (£228) [21], consistent with the estimates
used in our previous study [2].
Statistical methods
The data were hierarchically structured, in that multiple ADR
episodes can occur both within patients with multiple admissions
ADRs in Hospital In-Patients
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study collected data at the patient, admission, and ADR episode
level. To compare ADR incidence between hospital wards, a
generalised estimating equation (GEE) [22] model with compound
symmetry was used to account for the within-patient correlation.
This was considered more appropriate than a random effects
model when there are small numbers of observations within
patients [22].
For all other analyses, where a patient had multiple admissions
or multiple ADRs, we used a patient’s first ADR episode and
analysed at the patient level only. The first ADR episode was used
to simply assess the affected patient population and their risk
factors (age, gender, number of medicines and placement on a
medical or surgical ward) were identical or assumed to be broadly
similar for patients who had multiple admissions. Binary outcomes
were compared between groups using the chi-square statistic for
assessing significance. Comparisons between groups with respect
to continuous measures were made using the t-test or the Mann-
Whitney U-test, depending on skewness, for assessment of
statistical significance. The 5% level was used for assessing
significance.
Risk factors for ADRs were identified by investigating the effects
of age, gender, number of drugs prescribed and placement on a
medical or surgical ward, on the time to ADR. Regression analysis
was undertaken via the Cox proportional hazards model. Results
are given in terms of the hazard ratio (HR) for a particular factor
with accompanying 95% confidence interval (95%CI). The 5%
significance level was used when assessing factors for model
inclusion. The risk factor ‘number of regular drugs prescribed’
(calculated on day of admission where patient was taking most
regular medications for control sample patients) had data available
for 10% of the total sample (n=374), and therefore was only
investigated in this sample.
Results
Over six months, there were a total of 3695 patient episodes
assessed for ADRs involving 3322 patients. Out of these patient
episodes, 545 (14.7%, 95% CI 13.6–15.9%) resulted in one or
more ADRs. At the patient level, 524 of 3322 (15.8%) patients
experienced at least one ADR. Women experienced significantly
more ADRs (n=308, 17.8%) than men (n=216, 13.5%;
x
2=11.6, df=1, p,0.001). The median age was significantly
higher in the ADR group at 72 years (Q1–Q3 56–81 years)
compared with 61 years in the non-ADR group (Q1–Q3 41–77
years; U=109, p,0.0001). More medical patient episodes
(n=406, 16.0%) than surgical episodes (n=139, 12.0%) resulted
in ADRs (x
2=10.12, df=1, p,0.01). The incidence of ADR
episodes varied further according to the specialty of the wards
studied as shown in Table 1.The median length of stay for patient
episodes that resulted in an ADR was 20 days (Q1–Q3 12–
35 days), compared to 8 days (Q1–Q3 5–13 days; U=138,
p,0.0001) for those episodes without ADRs. Within the group
of patients experiencing an ADR, the mortality was higher (n=58,
10.7%), compared with 3.9% (n=126) of patients who did not
experience an ADR (x
2=42.4, df=1, p,0.0001). ADRs contrib-
uted to 14 out of the 184 deaths (0.4% of patients admitted, 8.2%
of all deaths), with one death (0.03% of patients admitted, 0.5% of
all deaths) being directly attributable to the ADR, specifically GI
bleed with diclofenac and dalteparin (see Table 2).
A total of 733 ADRs were identified. Type A ADRs accounted
for 690 (94.1%) of the ADRs while 232 (31.7%) ADRs fulfilled the
requirements for reporting to the UK regulatory agency. Drug-
drug interactions were linked to 433 (59.1%) of the ADRs; the
majority of these were pharmacodynamic in origin (91.7%), for
example, the use of multiple diuretics in patients with renal failure;
5.3% were pharmacokinetic, and 3% had a mixed pharmacoki-
netic-pharmacodynamic mechanism. The interactions will be
described in more detail elsewhere.
The majority (n=602, 82.1%) of the ADRs occurred as a result
of initiation of the causative drug in hospital, of which 390 (65%)
showed clinical signs. Similarly, of the 131 (62%) ADRs where the
drug had been initiated prior to hospital admission, with the ADR
occurring during admission, patients showed clinical signs in 81
(62%) cases. Tables 3 and 4 show detailed results of causality,
severity and avoidability assessments.
In patient episodes associated with an ADR, the number of
medicines taken was significantly higher (median 9, Q1–Q3 6–13)
than in those episodes not associated with an ADR (median 6,
Q1–Q3 4–10; U=92644; p,0.0001). The drug groups most
frequently implicated in the ADRs, and the frequency of their use
in the study population are shown in Table 5. The most frequent
causative drugs relative to usage were anticoagulants (warfarin),
fibrinolytics (streptokinase) (4 ADRs), unfractionated heparin (3
ADRs), loop diuretics and allopurinol (5 ADRs).
ADRs occurred despite prophylaxis in 67 (9.1%) cases involving
10 types of ADR (constipation (35), electrolyte disturbances (10),
renal failure (8), bleeding (5), raised INR (3), nausea (2), opioid
withdrawal, opioid dependence, oral Candidal infection, and
diarrhoea (all 1)). ADRs directly increased length of stay in 147
(27.0%) episodes, equating to 4.0% of all inpatient episodes and
accounting for 934 out of 50145 (1.9%) bed days or 0.25 days/
patient admission episode. For those episodes where length of stay
was directly increased by an ADR, the median increase was 4 days
(Q1–Q3, 2–7 days).
Table 6 gives results from multivariate risk factor analyses. The
only significant predictor was the number of medicines (p,0.0001;
HR 1.14; 95% CI 1.09, 1.20). Multivariable Cox regression
confirmed these results, with the number of medicines as the only
significant predictor. Therefore, on average, each additional
medication multiplies the hazard of an ADR episode by 1.14.
There may be a power issue in using the 10% sample, since the full
dataset showed that both gender and age were significant risk
Table 1. Odds of experiencing an adverse drug reaction by
ward type*.
Medical/Surgical
Specialty{
Odds ratio (95%CI) in
relation to breast/general
surgical ward{ (n=555)
Number of
patient
episodes
Respiratory 3.65 (2.37 to 5.61) 298
Cardiology 3.34 (2.13 to 5.25) 256
Endocrine 3.19 (2.02 to 5.06) 242
Elderly medicine 3.06 (2.07 to 4.55) 544
Orthopaedic surgery 2.65 (1.81 to 3.90) 711
Rheumatology 2.55 (1.27 to 5.13) 76
Gastrointestinal/ Liver 2.43 (1.58 to 3.73) 390
Pharmacology 1.53 (0.95 to 2.47) 356
Infectious diseases 1.28 (0.75 to 2.20) 267
*Method used: General Estimating Equation (GEE) model with compound
symmetry.
{One ward per specialty was assessed, with the exception of elderly medicine
and orthopaedic surgery where two wards were assessed.
{Odds Ratios adjusted for multilevel structure.
doi:10.1371/journal.pone.0004439.t001
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CI) 1.33 (1.12, 1.59) and 1.01 (1.0, 1.01) respectively). Comparing
these with the 10% sample showed that the mean values from the
full dataset were consistent with the 95% confidence intervals of
the 10% sample. Furthermore, the 10% sample was representative
of the whole sample set and unlikely to have introduced bias
(Table 7).
Discussion
This is the largest prospective study of adverse drug reactions in
UK hospital in-patients. Our data suggest that at least 1 in 7 in-
patient episodes is complicated by an adverse drug reaction. The
incidence figure of 14.7% is consistent with our pilot study [11].
However, our figure is higher than the 3.5–7.3% incidence
suggested in a systematic review [4]; this may be explained by the
fact that pooling data from ADR studies with different designs can
be problematical [23,24] as illustrated by the widely differing
estimates of ADR incidence determined in different studies in
different populations (from 0.86% [25], to 37% [26]). In order to
improve the accuracy of our assessments, individual causality
assessments were undertaken using the Naranjo causality assess-
Table 2. Deaths associated with adverse drug reactions.
Adverse drug
reaction
No associated
patient deaths Drugs (number of deaths)
Avoidability (definite, possible,
unavoidable)
Renal failure 7* Gentamicin (1), bumetanide, valsartan (1), bumetanide, furosemide,
spironolactone, ramipril (1), allopurinol, ceftriaxone, furosemide (1),
diclofenac (1), furosemide, spironolactone (1), bumetanide, metolazone,
perindopril, spironolactone, trimethoprim, potassium and calcium
supplements (sando K, sandocal) (1, included hypercalcemia
and hyperkalemia)
1 definite, 2 possible, 4 unavoidable
Clostridium
difficile infection
5* Ceftriaxone and ciprofloxacin and gentamicin (1), ceftriaxone,
ciprofloxacin, lansoprazole (1), amoxicillin, cefuroxime, ciprofloxacin
(plus lactulose and senna contributing to diarrhoea) (1), ceftriaxone,
erythromycin, clarithromycin, co-amoxiclav (1), ceftriaxone,
lansoprazole, trimethoprim (1)
3 possible, 2 unavoidable
GI Bleed 2 Dalteparin, diclofenac (1), aspirin, dalteparin, dipyridamole,
enoxaparin (1)
1 definite, 1 possible
Ischaemic bowel 1 Glypressin (1) 1 possible
*In one patient both renal failure and C.difficile infection contributed to death.
doi:10.1371/journal.pone.0004439.t002
Table 3. The adapted Hartwig severity scale and corresponding adverse drug reaction (ADR) frequency.
Severity Level Description
Frequency of the
ADR at each severity
level; n (%)*
1 An ADR occurred but no change in treatment with suspected drug 1 (0.1)
2 The ADR required that required treatment with the suspected drug be held, discontinued, or otherwise
changed. No antidote or other treatment required. No increase in length of stay
151 (20.6)
3 The ADR required that treatment with the suspected drug be held, discontinued, or otherwise
changed, and/or an antidote or other treatment. No increase in length of stay
413 (56.3)
4 Any Level 3 ADR which increases length of stay by at least one day OR the ADR was the reason
for admission
152 (20.7)
5 Any level 4 ADR which requires intensive medical care 1 (0.1)
6 The ADR caused permanent harm to the patient 0 (0.0)
7a The ADR was indirectly linked to death of patient 14 (1.9)
7b The ADR was directly linked to death of patient 1 (0.1)
*The denominator used was the total number of ADRs (n=733).
doi:10.1371/journal.pone.0004439.t003
Table 4. Causality and avoidability assessments of the
adverse drug reactions in hospital in-patients.
Assessment Category Frequency of ADRs (n; %)*
Causality Definite 23 (3.1)
Probable 487 (66.5)
Possible 223 (30.4
Avoidability Definite 47 (6.4)
Possible 344 (46.9)
Unavoidable 342 (46.7)
*Denominator used was the total number of ADRs, n=733.
doi:10.1371/journal.pone.0004439.t004
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and any disagreements were resolved by consensus discussions
with a third assessor. Causality assessments are difficult, and inter-
rater agreements vary enormously [27], but we feel that our
methods were as robust as is possible in relation to assessment of
individual cases. Thus, we feel that the prospective nature of this
study, and the intensive nature of data collection and follow-up,
similar in nature to two major recent studies of ADRs causing
admission [3,6] has resulted in, we believe, an accurate assessment
of ADRs in adult hospital inpatients.
A clear limitation of our study is that it was conducted in one
hospital and there is likely to be variation between different
hospitals because of differences in the local population character-
istics and the specialties within the hospitals. Nevertheless, we feel
that the study population was selected from 12 wards which were
representative of the clinical specialties (Table 1) commonly found
in most acute hospitals and the age distribution of our study
population was comparable to figures for all in-patient admissions
in England [28]. Hospital episode statistics from the Department
of Health in England state that in 2006–7 there were over 9
million adult admission episodes to NHS hospitals (excluding
Table 5. Drugs most frequently implicated in causing the adverse drug reactions (ADRs).
Drug group
No (%)
ADRs
Top ten
causative
drug groups
Rank by
frequency of
use of drugs
Drugs (number of ADRs
for each causative drug) Adverse drug reactions
Loop diuretics 151 (20.6) 1 14 Furosemide (123),
bumetanide (40)
Electrolyte disturbances, gout, hypotension,
ileus, nausea, renal failure
Opioids 118 (16.1) 2 1 Morphine (88), tramadol (53),
dihydrocodeine(10), fentanyl (8),
codeine(8), oxycodone (7),
pethidine (2)
Confusion, constipation, sedation, dizziness,
respiratory depression, hallucinations, ileus,
hypotension, itching, nausea, rash, dependence
Systemic corticosteroids 87 (11.9) 3 18 Prednisolone (67), dexamethasone
(14), hydrocortisone (11),
methylprednisolone (1),
fludrocortisone (1)
Electrolyte disturbances, increased INR,
bleeding, hallucination, hyperglycemia, fracture,
hypertension, neutropenia, candidal infection
Beta-agonists (inhaled) 85 (11.4) 4 12 Salbutamol (85), terbutaline (4),
salmeterol (3)
Electrolyte disturbances, nausea, tachycardia
Penicillins 66 (9.0) 5 6 Co-amoxiclav (34), amoxicillin (24),
flucloxacillin (15), benzylpenicillin
(7), penicillin v (1), ampicillin (1)
CDT, bleeding, rash, nausea, diarrhoea,
increased INR, candidal infection
Oral anticoagulants 72 (9.8) 6 52 Warfarin (72) Increased INR, bleeding
Cefalosporins 67 (9.1) 7 10 Ceftriaxone (40), cefuroxime (24),
cefradine (3), cefaclor (2),
Cefalexin (1), ceftazidime (1)
CDT, bleeding, increased INR, rash, nausea,
neutropenia, candidal infection, worsening renal
function
Compound analgesics
(with opioid)
64 (8.7) 8 8 Co-codamol (58), co-dydramol (7) Confusion, constipation, hypotension, sedation
Macrolide antibiotics 50 (6.8) 9 29 Erythromycin (34),
clarithromycin (27)
CDT, bleeding, renal failure, deranged LFTs,
diarrhoea, increased INR, rash, candidal
infection, nausea
Low molecular weight
heparins
50 (6.8) 10 6 Dalteparin (41), Enoxaparin (12) Bleeding, heparin induced thrombocytopenia,
electrolyte disturbances
Abbreviations: CDT – Clostridium difficile toxin disease; LFTs – liver function tests; INR – international normalised ratio.
doi:10.1371/journal.pone.0004439.t005
Table 6. Risk factors for adverse drug reaction assessed by multivariate analysis.
Factor N Parameter Estimate Standard Error Chi-sq (df) Pr.Chi Square Hazard Ratio
Gender (F v M) 374 20.026 0.24 0.012 (1) 0.9125 0.974
Ward Type (medical v surgical) 374 0.101 0.279 0.131 (1) 0.7178 1.106
Age 374 20.002 0.007 0.060 (1) 0.807 0.998
Number of medicines 374 0.13 0.025 26.617 (1) ,0.0001 1.138
doi:10.1371/journal.pone.0004439.t006
Table 7. Comparison of demographics of patients in 10%
sample with the remainder of the study population.
Factor
10% Sample
(n=374)
90% Remainder of study
population (n=2948)
Gender (% Male) 49% (n=185) 48% (n=1410)
Ward Type (% medical) 69% (n=258) 68% (n=2001)
Age (years, (median, Q1–Q3)) 62.5 (43–78) 63 (43–78)
doi:10.1371/journal.pone.0004439.t007
ADRs in Hospital In-Patients
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England, [29]. In our study, 1.9% of bed days were due to an
ADR. Therefore we estimate that approximately 2000 bed days
are due to an ADR at any one time, equivalent to approximately
three 800-bed hospitals at 85% capacity. This figure, added to the
estimate that the equivalent of seven 800-bed hospitals are filled
with patients admitted with ADRs [3], suggests that ADR-related
admissions and ADRs during hospitalization lead to the
occupancy of ten 800-bed NHS hospitals. An accurate assessment
of the financial cost of these ADRs is difficult, but a crude estimate
based on an average cost of a bed day in the NHS in England
suggests that the total costs are likely to exceed £171 million
annually for ADRs occurring during admission. This is however
likely to be an underestimate since the direct and indirect costs to
patients such as loss of earnings due to extended stay or increased
morbidity have not been measured, and neither were the costs
which could be attributed to treating ADRs such as the prescribing
of more medication and investigations, and involvement of clinical
team external to the specialty to which the patient was admitted,
all of which add to the overall ADR burden. As with our previous
study [3], however, the figures provided here need to be
interpreted cautiously as they represent an extrapolation from a
single hospital to the NHS as a whole. However, taken together
with our figure of £466 million for ADR-related admissions [3],
we would estimate that ADRs cost the NHS in England in excess
of £637 million annually, or approximately £5000 per hospital
bed per year. This figure is comparable with adverse drug event
(ADE) research from the United States ($8000 per hospital bed per
year) [30], and with ADR research from mainland Europe (£4700
per hospital bed per year) [31].
Implicated drugs and severity of reactions
The most frequently implicated drugs were opioid analgesics,
diuretics, systemic corticosteroids, anticoagulants and antibiotics.
This is in accordance with several other studies of hospital
inpatients [32–34]. When adjusted for the frequency of prescrip-
tion, warfarin, fibrinolytics and unfractionated heparin were the
top three causes of ADRs. It is worrying to note that the same
drugs, warfarin, loop diuretics and opioids, are being consistently
implicated in different studies of ADRs; this may partly reflect
their high usage, but nevertheless suggest that lessons have not
been learnt from previous studies, and effective preventive
strategies have not been put in place.
Approximately three quarters of adverse drug reactions were
scored at level 3 or below on the Hartwig scale (Table 3) and by
definition required intervention. These interventions ranged from
stopping the causative medicine(s) to administration of specific
antidotes, for example, naloxone for opioid-induced respiratory
depression. The remaining ADRs were sufficiently serious to result
in an increase in length of stay or admission to intensive care, and
in some cases, death. The assessment of whether an ADR has
increased the length of stay or caused death, and in particular
whether it is due to the underlying disease or due to an ADR, can
be extremely difficult; in our study, we undertook careful
assessment involving the clinical team whenever possible, and
taking into account individual patient factors such as the nature
and severity of the underlying disease, and social factors which
may have contributed to the length of stay more significantly than
the ADR itself. Our estimate therefore is likely to have been
relatively conservative.
Prevention of adverse drug reactions
In this study, just over half of the ADRs were deemed possibly
or definitely avoidable, which is consistent with the broad range of
figures (30–70%) suggested in the literature [35,36]. Given the
considerable burden of ADRs, there is a need to put into place
preventive strategies. Given the wide variety of drugs implicated,
and the huge array of ADRs that we identified affecting almost
every organ system in the body, prevention is likely to require
complex multi-faceted intervention strategies. In our study,
increasing age, admission to a medical ward, female gender, and
number of regular medicines were identified as risk factors.
Multivariable analysis of a representative sample of the data-set
(Tables 6 and 7) showed that the only significant risk factor was the
number of medicines the patient was taking, which may in itself be
a reflection of age, gender and status as a medical patient. This is
consistent with a number of previous studies [37–40]. Neverthe-
less, in order to confirm the results of our risk factor analysis it
would be desirable to repeat the study in a second cohort. Given
the increasing age of the population, and the trend towards
polypharmacy, even in younger patients, the problem of ADRs is
likely to remain a significant, if not increasing burden on our
hospitals. Computerised prescribing and monitoring systems [41–
43], the presence of pharmacists on ward rounds [44,45], the need
for better monitoring [46], and enhanced education of prescribing,
leading to error reduction [47], are amongst the possible
intervention strategies that have been suggested to be important
in reducing the burden of ADRs. There is however a need for
further research in this area, not only for the development of a
robust evidence base to allow for prevention of ADRs, but also in
the implementation of these strategies into hospital healthcare
systems. Although it would be prudent to initially focus on the
more serious ADRs, it is important to remember that even so-
called non-serious ADRs, for example constipation from using
opioids, can have a significant impact on the patient’s quality of
life, and also require the development of preventive strategies.
In conclusion, our study shows that ADRs are a significant
problem in hospital inpatients, contributing to morbidity and
mortality and resulting in considerable financial burden. Over half
are definitely or potentially avoidable, and steps should be taken to
introduce strategies to reduce their impact.
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